Olanzapine/Fluoxetine (Symbyax): Uses, Dosing, Side Effects, and Metabolic Risks

What It's Used For

Olanzapine/fluoxetine (Symbyax) is not a first-line antidepressant. It’s a heavier-hitting option used when standard treatments aren’t enough or when depression is part of bipolar I disorder.

Primary Indications

Bipolar I depression: Acute depressive episodes in bipolar I disorder, especially when symptoms are severe, disabling, or associated with suicidality.Treatment-resistant depression (TRD): Major depressive episodes that have not responded to at least 2 adequate trials of different antidepressants in the current episode.Evening dosing: Usually taken at night because olanzapine is sedating and can increase appetite.

Off-Label Uses

Not typically used off-label beyond its approved indications; other antipsychotic/antidepressant strategies are preferred for most off-label situations.Not appropriate for behavioral symptoms of dementia-related psychosis due to increased mortality and stroke risk.

How Fast It Works

This is not a quick PRN medication. It’s a daily mood treatment that builds in your system over time. One component (fluoxetine) has a very long half-life, so changes in dose take days to weeks to fully show up.

First week

Sleep and appetite often change first. Some people feel sedated, others feel a bit activated or restless.

2–4 weeks

Early mood benefits may show up—less hopelessness, fewer crying spells, better ability to get out of bed and function.

4–8 weeks

Full antidepressant effect is typically evaluated. If there’s going to be a meaningful response, clinicians usually see it by this window.

All day coverage

Once-daily dosing provides 24-hour coverage because both drugs have long half-lives.

Long tail

Fluoxetine and its metabolite linger for weeks after discontinuation, so side effects and interactions can persist after you stop.

Safe Discontinuation

Because Symbyax combines a long half-life SSRI with an antipsychotic, discontinuation needs to be deliberate. Suddenly stopping can cause withdrawal symptoms and mood destabilization, but fluoxetine’s long half-life can also create a “built-in” slow taper for the SSRI component.

Key Points

Never stop abruptly without guidance, especially if you’ve been on it for months or years.
Olanzapine taper: Gradually reduce the dose over weeks to months to avoid rebound insomnia, agitation, mood worsening, and antipsychotic withdrawal symptoms (restlessness, GI upset, anxiety, flu-like symptoms).
Fluoxetine taper: Because of the long half-life, SSRI discontinuation symptoms are usually milder than with shorter-acting SSRIs, but mood symptoms can still return. Taper is still recommended.
Typical clinical approach: Reduce total daily dose by about 25% every 1–2 weeks, slowing the taper if significant withdrawal symptoms or mood relapse occur.
Switching strategies: If transitioning to another antidepressant or antipsychotic, be mindful that fluoxetine and norfluoxetine may persist for weeks and interact with the new medication.
Monitoring during taper: Watch for return of depressive symptoms, suicidality, hypomania/mania, or new anxiety and insomnia. Pause or slow the taper if symptoms spike.

Dosing Information

Adult Dosing

bipolar depression initial: Olanzapine 6 mg / fluoxetine 25 mg PO once nightly. Consider starting at 3 mg / 25 mg nightly in patients prone to hypotension, with hepatic impairment, slower metabolism (female, nonsmoker), or high sensitivity to sedation.

bipolar depression titration: Adjust based on response and tolerability; increase olanzapine in 3–6 mg steps and fluoxetine in 25 mg steps, no more frequently than every several days to a week.

bipolar depression target: Usual range: olanzapine 6–12 mg / fluoxetine 25–50 mg PO once nightly. Safety of olanzapine doses >18 mg or fluoxetine >75 mg daily in combination has not been established.

trd initial: Olanzapine 6 mg / fluoxetine 25 mg PO once nightly appended to a history of at least 2 prior failed antidepressant trials in the current episode.

trd titration: Increase slowly based on mood response, sedation, weight, and metabolic labs. Adjust olanzapine and fluoxetine as above; titrate more cautiously in those with hepatic impairment or multiple comorbidities.

trd target: Usual range: olanzapine 6–18 mg / fluoxetine 25–50 mg PO once nightly. Avoid pushing past this range without subspecialty input due to metabolic and neurologic risks.

switching maoi: Allow at least 14 days between stopping an MAOI and starting olanzapine/fluoxetine. After stopping olanzapine/fluoxetine, wait at least 5 weeks before starting an MAOI due to fluoxetine’s long half-life.

hepatic impairment: Start at lower doses (olanzapine 3–6 mg / fluoxetine 25 mg nightly) and titrate slowly; clearance is reduced and side effects may be amplified.

renal impairment: No routine adjustment in mild-to-severe renal impairment, but monitor more closely; comorbidities often increase sensitivity.

elderly: Start low and go slow (e.g., olanzapine 3–6 mg / fluoxetine 25 mg nightly). Avoid use for dementia-related behaviors. Monitor sodium, falls, and cognition closely.

Simple Explanation

Think of Symbyax as a night-time, long-acting mood medicine. We start at a modest dose, see how your sleep, mood, and side effects behave over a few weeks, and then carefully adjust. The goal is to get enough antidepressant and mood-stabilizing effect without letting weight, blood sugar, cholesterol, or movement side effects spiral out of control.

Available Formulations

Symbyax capsules (brand): Olanzapine 3 mg / fluoxetine 25 mg; 6 mg / 25 mg.
Generic olanzapine/fluoxetine capsules: 3 mg / 25 mg; 6 mg / 25 mg; 6 mg / 50 mg; 12 mg / 25 mg; 12 mg / 50 mg.
Individual components (used when more flexible dosing is needed): Olanzapine tablets (multiple strengths) and fluoxetine capsules/tablets or liquid.

Critical Safety Information

Boxed warnings: (1) Higher risk of suicidal thoughts and behaviors in children, teens, and young adults. (2) Higher risk of death in older adults with dementia-related psychosis.

→You and your family should watch closely for new or worse suicidal thoughts, severe agitation, panic, or dramatic mood swings—especially in the first 1–2 months. If these show up, call your prescriber or go to the ER.
→This medication can cause significant weight gain and metabolic changes. Expect regular labs (glucose, A1C, lipids) and weight/BMI monitoring.
→Report symptoms like high thirst, frequent urination, blurry vision, or unexplained fatigue—these can signal high blood sugar.
→Tell your clinician about any menstrual changes, breast discharge, breast enlargement, or sexual side effects.
→Seek emergency care for fever, muscle stiffness, confusion, or autonomic instability (possible neuroleptic malignant syndrome).
→Seek urgent care for rash with fever, swollen lymph nodes, or organ symptoms (possible DRESS).
→Avoid sudden discontinuation unless directed. Both mood symptoms and withdrawal symptoms can flare if stopped abruptly.
→Avoid combining with other serotonergic meds or QT-prolonging meds without explicit prescriber guidance.

Side Effects

The big three with olanzapine/fluoxetine are: (1) weight gain and metabolic changes, (2) sedation and fatigue, and (3) hormonal and movement-related side effects. These can be dose-related and cumulative over time.

Common Things People Notice

Weight gain and increased appetite (very common, often >7% of baseline weight).
Increased cholesterol and triglycerides; decreased “good” HDL.
Sedation, drowsiness, and fatigue—especially early on or after dose increases.
Dry mouth, increased appetite, and GI changes (bloating, nausea, or indigestion).
Hormonal changes like increased prolactin (irregular periods, breast changes, sexual dysfunction).
Tremor, restlessness, or other movement symptoms in some people.
Changes in liver enzymes on blood tests.
Orthostatic dizziness or feeling lightheaded when standing up.

Common Side Effects

Very common (weight gain ≥7% of baseline; dyslipidemia and hypertriglyceridemia frequently reported in both adults and youth).

Weight Gain and Metabolic Changes— This medication is notorious for increasing appetite and causing weight gain. It also raises cholesterol, triglycerides, and can push people toward prediabetes or diabetes. Plan from day one: nutrition, movement, and regular labs are part of treatment, not optional extras.

About 1 in 4 or more experience significant sedation.

Sedation, Drowsiness, and Fatigue— Many people feel very sleepy, especially at the beginning or after dose changes. Taking it at night helps. If you’re too groggy in the morning to function, talk with your prescriber about dose timing or adjustment.

Increased appetite and dry mouth reported in ~15–20% or more.

Increased Appetite and Dry Mouth— You might find yourself constantly snacking or craving carbs, plus feeling like your mouth is a desert. Sugar-free gum, water, and structured meals can help—but the appetite effect can be powerful.

High rates of increased LDL, total cholesterol, and triglycerides; risk of hyperglycemia.

Lipid and Glucose Changes— These are usually silent—you don’t feel them until there’s a problem. That's why regular blood work matters. We’re not being annoying with labs; we’re trying to protect your heart and pancreas.

Common, especially in youth; prolactin elevation reported in a large proportion of patients.

Hyperprolactinemia and Sexual Side Effects— You may notice menstrual changes, breast tenderness or discharge, low libido, or sexual dysfunction. These are medication side effects, not “in your head,” and they’re important to bring up.

Tremor and restlessness occur in a noticeable minority of patients.

Tremor, Restlessness, and Other Movement Symptoms— Some people feel jittery, can’t sit still (akathisia), or develop tremor or stiffness. These may be subtle early on. Report them quickly; dose changes or meds to counteract EPS may help.

Serious side effects

Suicidal thoughts or behaviors, particularly in children, adolescents, and young adults—requires close monitoring and may require dose change or discontinuation.
Neuroleptic malignant syndrome (NMS): fever, muscle rigidity, confusion, autonomic instability—medical emergency.
Serotonin syndrome: agitation, confusion, sweating, tremor, clonus, fever, diarrhea—especially with other serotonergic drugs; requires prompt discontinuation and urgent care.
DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms): rash, fever, swollen lymph nodes, organ dysfunction—can be life-threatening.
Severe hyperglycemia and diabetic complications (ketoacidosis, hyperosmolar states).
Significant hyponatremia/SIADH: confusion, headache, seizures, or falls—more common in older adults and those on diuretics.
QT prolongation and ventricular arrhythmias, particularly with other QT-prolonging agents or electrolyte disturbances.
Extrapyramidal symptoms and tardive dyskinesia: potentially irreversible abnormal movements, especially with long-term use and in older adults.
Agranulocytosis, neutropenia, and other blood dyscrasias: unexplained infections, fever, or sore throat may be warning signs.
Venous thromboembolism (DVT, pulmonary embolism), sometimes serious or fatal.
Hepatic injury: significant elevations in liver enzymes, rare cases of serious liver disease.
Pulmonary issues like aspiration pneumonia or, rarely, pulmonary fibrosis, particularly in vulnerable populations.

Critical Drug Interactions

Olanzapine/fluoxetine interacts with many other medications through serotonin effects, cardiac conduction (QT interval), bleeding risk, and cytochrome P450 metabolism. Always run interaction checks before adding new meds.

With: Monoamine Oxidase Inhibitors (MAOIs) and IV Methylene Blue

Risk: High risk of serotonin syndrome and hypertensive reactions.

Action: Contraindicated. Allow at least 14 days between stopping an MAOI and starting olanzapine/fluoxetine. Wait at least 5 weeks after stopping olanzapine/fluoxetine before starting an MAOI or methylene blue.

With: Pimozide or Thioridazine

Risk: Marked QT prolongation and risk of life-threatening arrhythmias.

Action: Contraindicated. Thioridazine should not be started until 5 weeks after discontinuing fluoxetine or this combination.

With: Other Serotonergic Medications (triptans, SNRIs, TCAs, tramadol, fentanyl, lithium, MAOIs, linezolid, St John’s wort, amphetamines)

Risk: Increased risk of serotonin syndrome (agitation, autonomic instability, neuromuscular changes, GI symptoms).

Action: Avoid or use extreme caution. Educate patients on early signs of serotonin syndrome and instruct them to seek urgent care if symptoms appear.

With: Drugs that Prolong QT Interval (certain antipsychotics, antiarrhythmics, macrolides, fluoroquinolones, methadone)

Risk: Additive QT prolongation increases risk of torsade de pointes and sudden death.

Action: Avoid high-risk combinations when possible. If necessary, correct electrolytes, obtain baseline and follow-up ECGs, and use the lowest effective doses.

With: Anticoagulants, Antiplatelets, and NSAIDs

Risk: Fluoxetine impairs platelet aggregation and can increase bleeding risk, especially GI bleeding and postpartum hemorrhage.

Action: Use caution; discuss bleeding risks, watch for bruising, nosebleeds, black stools, or blood in urine.

With: Other CNS Depressants (benzodiazepines, opioids, sedative hypnotics, alcohol, antihistamines, muscle relaxants)

Risk: Additive sedation, respiratory depression, falls, and cognitive impairment.

Action: Use the lowest effective doses, avoid alcohol, and counsel on fall and driving risk. Reassess the need for multiple sedating medications.

With: CYP2D6 Inhibitors or Substrates (e.g., some SSRIs, TCAs, antipsychotics, codeine, tamoxifen)

Risk: Fluoxetine is a strong CYP2D6 inhibitor—can raise levels of other CYP2D6 substrates and reduce conversion of prodrugs like codeine and tamoxifen.

Action: Review all meds for CYP2D6 substrates. Dose adjustments or alternative agents may be needed.

With: CYP1A2 Inducers (smoking, carbamazepine) or Inhibitors

Risk: Olanzapine is metabolized by CYP1A2; smokers may have lower levels and less effect, while inhibitors can increase levels.

Action: Tell your prescriber if you start or stop smoking, or start or stop CYP1A2 modulators, so they can watch how you respond; the dose may need to change.

With: Diuretics and Other Hyponatremia-Risk Drugs

Risk: Increased risk of SIADH and hyponatremia with SSRIs.

Action: Monitor sodium, especially in older adults and those with volume depletion or diuretic use.

Pregnancy, Breastfeeding, Special Groups

This combination crosses the placenta and enters breast milk. It also hits multiple organ systems (metabolic, neurologic, hormonal), so extra caution is needed in pregnancy, breastfeeding, older adults, and those with medical comorbidities.

👶Pregnancy

Both olanzapine and fluoxetine cross the placenta. Third-trimester exposure to antipsychotics or SSRIs can be associated with neonatal adaptation syndrome (jitteriness, respiratory distress, feeding issues) and, rarely, persistent pulmonary hypertension. SSRIs have mixed data on congenital malformations; antipsychotics carry metabolic and weight-related risks that can compound pregnancy complications. Use only when the benefits of mood stabilization clearly outweigh fetal and obstetric risks, and ideally in coordination with perinatal psychiatry and obstetrics.

🤱Breastfeeding

Olanzapine and fluoxetine are excreted in breast milk. Infant exposure can lead to sedation, feeding difficulties, irritability, or poor weight gain. If treatment is essential and no safer alternatives are appropriate, use the lowest effective dose, monitor the infant for sedation, poor feeding, weight changes, and developmental concerns, and coordinate care with pediatrics.

👧Children & Adolescents (Under 18)

Approved for bipolar I depression in children ≥10 years and adolescents. Not approved in children <10. Kids and teens are more prone to metabolic side effects (weight gain, lipid changes), hyperprolactinemia, and extrapyramidal symptoms. There is also a suicidality black box warning in younger patients. Use only when clearly indicated, with very close monitoring of weight, BMI, waist circumference, and labs.

👴Older Adults (65+)

In adults ≥65, Symbyax is high-risk. Antipsychotics increase stroke and mortality risk in dementia-related psychosis and can worsen cognition and falls. SSRIs and antipsychotics both increase SIADH/hyponatremia risk. If used (e.g., for severe bipolar depression), start at very low doses, monitor sodium, falls, gait, and cognition, and regularly reassess ongoing need.

🔬Liver Impairment

Both components are hepatically metabolized. In hepatic impairment, start at the lowest dose (often olanzapine 3–6 mg / fluoxetine 25 mg nightly) and titrate slowly with frequent monitoring for sedation, metabolic issues, and liver function abnormalities.

💧Kidney Impairment

No standard dose adjustment is required in renal impairment, but comorbidities (diabetes, cardiovascular disease) often magnify risks. Monitor metabolic parameters and volume status closely, and consider dose reductions if side effects emerge.

Clinical Monitoring

Mental health and suicidality: At every visit, assess mood, anxiety, suicidality, agitation, hypomania/mania, and overall functioning—especially in the first 1–2 months and after dose changes.
Adherence: Check at every visit. Nonadherence is common when side effects (weight gain, fatigue) show up before benefits.
Weight, BMI, and waist circumference: Baseline; then at 8 and 12 weeks, after dose changes, and at least quarterly. Consider more frequent checks early on.
Metabolic labs: Fasting glucose/A1C and lipid panel at baseline, ~4 months after initiation, and annually (more often if abnormal or high-risk).
Electrolytes and basic chemistries: At least annually; monitor sodium more closely in older adults, those on diuretics, or those with symptoms of hyponatremia.
CBC: As clinically indicated, and more frequently if history of low WBC or drug-induced leukopenia/neutropenia; monitor for signs of infection.
Liver function tests: Baseline and periodically in long-term use, or if symptoms suggest liver problems (fatigue, jaundice, dark urine, RUQ pain).
ECG: at the start and when needed if you have heart disease, abnormal blood salts, or take other QT-prolonging medicines.
Movement disorders (EPS and tardive dyskinesia): Assess at every visit; use a structured rating scale at least annually or every 6 months if higher risk.
Prolactin-related symptoms: Ask regularly about menstrual changes, libido, gynecomastia, galactorrhea, and sexual dysfunction; measure prolactin if symptoms are present.
Falls and gait: Especially in older adults—check for dizziness, orthostatic hypotension, and gait instability at each visit.
Signs of serotonin syndrome: New agitation, confusion, tremor, clonus, sweating, or diarrhea—especially when other serotonergic meds are present.
Global functioning: Track work/school performance, social functioning, and quality of life to ensure benefits outweigh side effects over time.

How Well It Works

Response Rate in Severe or Treatment-Resistant Depression

≈45–60% response

vs Higher response than placebo and higher than antidepressant alone in treatment-resistant depression, at the cost of significant metabolic side effects.

Olanzapine/fluoxetine sits in the “heavy artillery” category: it’s not the first thing we reach for, but when standard antidepressants have failed or when bipolar depression is severe, this combination can move the needle. The tradeoff is that the same olanzapine that boosts mood stability also drives weight gain, cholesterol changes, and blood sugar problems in a sizable chunk of patients.

Mechanism of Action

Olanzapine/fluoxetine works by hitting mood from two major angles at once. Fluoxetine is an SSRI that increases serotonin in synapses by blocking its reuptake. Olanzapine is an atypical antipsychotic that blocks multiple receptors, including serotonin (5-HT2A and 5-HT2C), dopamine (D2 and others), histamine (H1), and alpha-1 adrenergic receptors, with moderate activity at muscarinic receptors. Together, they boost serotonin while modulating dopamine and other neurotransmitters. This combination can deepen antidepressant effects and stabilize mood in bipolar depression, but the same receptor actions drive weight gain, metabolic changes, sedation, and movement disorders.

Place in Treatment Algorithm

In modern practice, olanzapine/fluoxetine is a second- or third-line option, not a starter antidepressant. For bipolar depression, first-line options often include mood stabilizers and other atypical antipsychotics with fewer weight and blood sugar effects. For treatment-resistant depression, clinicians usually try several strategies first (different SSRIs/SNRIs, adding lithium, other atypical antipsychotics, or psychotherapy). It is usually kept for situations where the depression is severe, clearly bipolar or treatment-resistant, and you and your prescriber are willing to accept significant weight and metabolic risks for a better chance of real mood improvement. It should be avoided for dementia-related behaviors and used cautiously and for limited periods in young people and older adults.

Questions people ask

What is Symbyax (olanzapine/fluoxetine) actually used for?

Symbyax is used for two main things: (1) episodes of depression in bipolar I disorder, and (2) depression that has not responded to at least two antidepressants tried at a proper dose and for long enough in the current episode (treatment-resistant depression). It is not one of the antidepressants usually tried first for mild or moderate depression and should not be used for dementia-related behaviors.

How long does Symbyax take to work?

Sleep and appetite changes often show up within days. Mood and energy usually start to shift over 2–4 weeks, with full benefit often judged after 6–8 weeks. Because fluoxetine and its metabolite hang around for a long time, dose changes can take a couple of weeks to fully show up—this is a slow-steady medication, not an instant fix.

Is Symbyax good for anxiety or only depression?

The main targets are bipolar depression and treatment-resistant major depression. However, because it contains an SSRI (fluoxetine) and a sedating antipsychotic (olanzapine), anxiety symptoms often improve as mood stabilizes and sleep gets better. That said, it’s not usually chosen just for anxiety due to its heavy metabolic and neurologic side-effect profile.

Does Symbyax cause weight gain?

Yes—this is one of the biggest downsides. Olanzapine is strongly associated with increased appetite, weight gain, and metabolic changes (increased triglycerides, cholesterol, and blood sugar). Many people gain more than 7% of their starting weight. If you use Symbyax, you need a proactive plan: nutrition, physical activity, regular weight/BMI checks, and lab monitoring (glucose/A1C and lipids).

What about diabetes and cholesterol—how worried should I be?

Concerned enough to take monitoring seriously. Symbyax can push people toward insulin resistance, high triglycerides, and high LDL cholesterol. Some people with risk factors (family history, obesity) may develop diabetes. That is why guidelines recommend fasting blood sugar or A1C and cholesterol tests at the start and over time, plus ongoing weight and waist measurements.

Can Symbyax make suicidal thoughts worse?

In children, adolescents, and young adults, antidepressants—including this combination—carry a black box warning for increased risk of suicidal thoughts and behaviors early in treatment or when doses change. For adults over 24, this risk does not appear increased overall, and adults over 65 may even have a reduced risk. Regardless of age, any new or worsening suicidal thoughts, self-harm behaviors, or severe agitation are red flags and need immediate attention.

Can older adults take Symbyax?

They can, but it is high risk and must be done very carefully. In older adults, the antipsychotic part raises the risk of stroke, falls, weight and blood sugar problems, and, in people with dementia, death. SSRIs and antipsychotics also raise the risk of low blood sodium (hyponatremia). If an older adult needs Symbyax for severe bipolar depression or depression that has not responded to other treatment, it is started at very low doses, watched closely (including sodium and fall risk), and the benefits are reviewed regularly to make sure they still justify the risks.

Is Symbyax the same as taking Prozac plus Zyprexa separately?

Pharmacologically, it’s the same drugs—fluoxetine and olanzapine—but in fixed-dose capsule combinations. Taking them separately can give more flexibility (for example, slightly different ratios or lower starting doses than the capsules allow), which is sometimes helpful in patients who are very sensitive to side effects. The fixed-dose combo is convenient but less customizable.

Can I drink alcohol with Symbyax?

It’s strongly discouraged. Both components can cause sedation, and combining them with alcohol increases the risk of excessive drowsiness, poor judgment, falls, and accidents. Alcohol can also worsen mood and sleep, and may amplify metabolic issues. If you drink, talk honestly with your prescriber so you can make a realistic and safe plan.

Is Symbyax used for mania or psychosis?

No. Symbyax is approved for bipolar depression, not mania or mixed episodes. Using antidepressants in mania or mixed states can actually make things worse. If someone presents with manic or mixed symptoms, the priority is mood stabilization with appropriate antimanic treatments—not this combination.

What kind of monitoring should I expect if I start Symbyax?

You should expect: weight, BMI, and possibly waist circumference checks; fasting glucose or A1C and lipid panels; periodic liver function tests; basic electrolytes (especially sodium in older adults); movement checks for tremor or abnormal movements; and regular mood/suicidality assessments. If no one is monitoring these things, that’s a problem—bring it up.

How long do people usually stay on Symbyax?

It depends on why it was started and how you’re tolerating it. For acute bipolar depression or a severe TRD episode, many clinicians aim for months of stability before considering dose reduction or switching to something with a gentler metabolic profile. Long-term use is possible but should never be “set and forget”—periodically reassess whether you still need it, whether the dose can be reduced, or whether another option might give you similar mood benefits with fewer physical risks.